Congenital long QT syndrome and 2: 1 atrioventricular block: An optimistic outcome in the current era

Peter F. Aziz, Ronn E. Tanel, Ilana J. Zelster, Robert H. Pass, Tammy S. Wieand, Victoria L. Vetter, R. Lee Vogel, Maully J. Shah

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Previous studies of patients with long QT syndrome (LQTS) and 2:1 atrioventricular block (AVB) have reported a mortality rate greater than 50% during infancy. Objective: The purpose of this study was to determine the outcome of this high-risk population in the current era. Methods: A retrospective study from four tertiary care pediatric centers assessed patients with congenital LQTS and 2:1 AVB from January 2000 to January 2009. All neonates who presented with 2:1 AVB and prolonged QTc unrelated to medication were included in the study. Statistical analysis was performed using a paired t-test. Medical records were reviewed for ECG findings, genotype, medications, and device therapy. Results: Twelve patients that met the inclusion criteria were identified. All patients underwent diagnostic ECG in the first 24 hours of life. The average QTc interval prior to therapy was 616 ± 99 ms (range 531-840 ms). Over a follow-up period of 71 ± 45 months (range 15-158 months), 11 of 12 patients received devices (8 permanent pacemaker, 3 implantable cardioverter-defibrillator). Average age of device placement was 48 months (median 2 months, range 3 days to 10.5 years). All patients were treated with beta-blockers; mexiletine was added in three patients, and mexiletine and flecainide were added in one patient. Three (25%) patients experienced torsades de pointes while receiving beta-blockers, one of which was refractory to medical therapy. This patient underwent left cardiac sympathetic denervation and implantable cardioverter-defibrillator placement. Genotyping was available for 6 (50%) patients (2 SCN5A mutation, 4 KCNH2 mutation). At last follow-up, no mortality was observed. Follow-up QTc intervals had decreased (mean 480 ± 20 ms, range 450-507 ms, P <.002). Conclusion: Management of patients with LQTS and 2:1 AVB presents unique challenges. Despite historical data indicating poor prognosis, our study represents a cohort of high-risk LQTS patients with a relatively optimistic outcome. This finding reflects early diagnosis and intervention, coupled with improved management strategies, in the current era.

Original languageEnglish (US)
Pages (from-to)781-785
Number of pages5
JournalHeart Rhythm
Volume7
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Romano-Ward Syndrome
Atrioventricular Block
Mexiletine
Implantable Defibrillators
Equipment and Supplies
Electrocardiography
Flecainide
Torsades de Pointes
Long QT Syndrome
Mutation
Sympathectomy
Mortality

Keywords

  • Atrioventricular block
  • Long QT syndrome
  • Torsades de pointes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Aziz, P. F., Tanel, R. E., Zelster, I. J., Pass, R. H., Wieand, T. S., Vetter, V. L., ... Shah, M. J. (2010). Congenital long QT syndrome and 2: 1 atrioventricular block: An optimistic outcome in the current era. Heart Rhythm, 7(6), 781-785. https://doi.org/10.1016/j.hrthm.2010.02.035

Congenital long QT syndrome and 2 : 1 atrioventricular block: An optimistic outcome in the current era. / Aziz, Peter F.; Tanel, Ronn E.; Zelster, Ilana J.; Pass, Robert H.; Wieand, Tammy S.; Vetter, Victoria L.; Vogel, R. Lee; Shah, Maully J.

In: Heart Rhythm, Vol. 7, No. 6, 06.2010, p. 781-785.

Research output: Contribution to journalArticle

Aziz, PF, Tanel, RE, Zelster, IJ, Pass, RH, Wieand, TS, Vetter, VL, Vogel, RL & Shah, MJ 2010, 'Congenital long QT syndrome and 2: 1 atrioventricular block: An optimistic outcome in the current era', Heart Rhythm, vol. 7, no. 6, pp. 781-785. https://doi.org/10.1016/j.hrthm.2010.02.035
Aziz, Peter F. ; Tanel, Ronn E. ; Zelster, Ilana J. ; Pass, Robert H. ; Wieand, Tammy S. ; Vetter, Victoria L. ; Vogel, R. Lee ; Shah, Maully J. / Congenital long QT syndrome and 2 : 1 atrioventricular block: An optimistic outcome in the current era. In: Heart Rhythm. 2010 ; Vol. 7, No. 6. pp. 781-785.
@article{a9e43ffe2f26464c973b1bed46389f48,
title = "Congenital long QT syndrome and 2: 1 atrioventricular block: An optimistic outcome in the current era",
abstract = "Background: Previous studies of patients with long QT syndrome (LQTS) and 2:1 atrioventricular block (AVB) have reported a mortality rate greater than 50{\%} during infancy. Objective: The purpose of this study was to determine the outcome of this high-risk population in the current era. Methods: A retrospective study from four tertiary care pediatric centers assessed patients with congenital LQTS and 2:1 AVB from January 2000 to January 2009. All neonates who presented with 2:1 AVB and prolonged QTc unrelated to medication were included in the study. Statistical analysis was performed using a paired t-test. Medical records were reviewed for ECG findings, genotype, medications, and device therapy. Results: Twelve patients that met the inclusion criteria were identified. All patients underwent diagnostic ECG in the first 24 hours of life. The average QTc interval prior to therapy was 616 ± 99 ms (range 531-840 ms). Over a follow-up period of 71 ± 45 months (range 15-158 months), 11 of 12 patients received devices (8 permanent pacemaker, 3 implantable cardioverter-defibrillator). Average age of device placement was 48 months (median 2 months, range 3 days to 10.5 years). All patients were treated with beta-blockers; mexiletine was added in three patients, and mexiletine and flecainide were added in one patient. Three (25{\%}) patients experienced torsades de pointes while receiving beta-blockers, one of which was refractory to medical therapy. This patient underwent left cardiac sympathetic denervation and implantable cardioverter-defibrillator placement. Genotyping was available for 6 (50{\%}) patients (2 SCN5A mutation, 4 KCNH2 mutation). At last follow-up, no mortality was observed. Follow-up QTc intervals had decreased (mean 480 ± 20 ms, range 450-507 ms, P <.002). Conclusion: Management of patients with LQTS and 2:1 AVB presents unique challenges. Despite historical data indicating poor prognosis, our study represents a cohort of high-risk LQTS patients with a relatively optimistic outcome. This finding reflects early diagnosis and intervention, coupled with improved management strategies, in the current era.",
keywords = "Atrioventricular block, Long QT syndrome, Torsades de pointes",
author = "Aziz, {Peter F.} and Tanel, {Ronn E.} and Zelster, {Ilana J.} and Pass, {Robert H.} and Wieand, {Tammy S.} and Vetter, {Victoria L.} and Vogel, {R. Lee} and Shah, {Maully J.}",
year = "2010",
month = "6",
doi = "10.1016/j.hrthm.2010.02.035",
language = "English (US)",
volume = "7",
pages = "781--785",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Congenital long QT syndrome and 2

T2 - 1 atrioventricular block: An optimistic outcome in the current era

AU - Aziz, Peter F.

AU - Tanel, Ronn E.

AU - Zelster, Ilana J.

AU - Pass, Robert H.

AU - Wieand, Tammy S.

AU - Vetter, Victoria L.

AU - Vogel, R. Lee

AU - Shah, Maully J.

PY - 2010/6

Y1 - 2010/6

N2 - Background: Previous studies of patients with long QT syndrome (LQTS) and 2:1 atrioventricular block (AVB) have reported a mortality rate greater than 50% during infancy. Objective: The purpose of this study was to determine the outcome of this high-risk population in the current era. Methods: A retrospective study from four tertiary care pediatric centers assessed patients with congenital LQTS and 2:1 AVB from January 2000 to January 2009. All neonates who presented with 2:1 AVB and prolonged QTc unrelated to medication were included in the study. Statistical analysis was performed using a paired t-test. Medical records were reviewed for ECG findings, genotype, medications, and device therapy. Results: Twelve patients that met the inclusion criteria were identified. All patients underwent diagnostic ECG in the first 24 hours of life. The average QTc interval prior to therapy was 616 ± 99 ms (range 531-840 ms). Over a follow-up period of 71 ± 45 months (range 15-158 months), 11 of 12 patients received devices (8 permanent pacemaker, 3 implantable cardioverter-defibrillator). Average age of device placement was 48 months (median 2 months, range 3 days to 10.5 years). All patients were treated with beta-blockers; mexiletine was added in three patients, and mexiletine and flecainide were added in one patient. Three (25%) patients experienced torsades de pointes while receiving beta-blockers, one of which was refractory to medical therapy. This patient underwent left cardiac sympathetic denervation and implantable cardioverter-defibrillator placement. Genotyping was available for 6 (50%) patients (2 SCN5A mutation, 4 KCNH2 mutation). At last follow-up, no mortality was observed. Follow-up QTc intervals had decreased (mean 480 ± 20 ms, range 450-507 ms, P <.002). Conclusion: Management of patients with LQTS and 2:1 AVB presents unique challenges. Despite historical data indicating poor prognosis, our study represents a cohort of high-risk LQTS patients with a relatively optimistic outcome. This finding reflects early diagnosis and intervention, coupled with improved management strategies, in the current era.

AB - Background: Previous studies of patients with long QT syndrome (LQTS) and 2:1 atrioventricular block (AVB) have reported a mortality rate greater than 50% during infancy. Objective: The purpose of this study was to determine the outcome of this high-risk population in the current era. Methods: A retrospective study from four tertiary care pediatric centers assessed patients with congenital LQTS and 2:1 AVB from January 2000 to January 2009. All neonates who presented with 2:1 AVB and prolonged QTc unrelated to medication were included in the study. Statistical analysis was performed using a paired t-test. Medical records were reviewed for ECG findings, genotype, medications, and device therapy. Results: Twelve patients that met the inclusion criteria were identified. All patients underwent diagnostic ECG in the first 24 hours of life. The average QTc interval prior to therapy was 616 ± 99 ms (range 531-840 ms). Over a follow-up period of 71 ± 45 months (range 15-158 months), 11 of 12 patients received devices (8 permanent pacemaker, 3 implantable cardioverter-defibrillator). Average age of device placement was 48 months (median 2 months, range 3 days to 10.5 years). All patients were treated with beta-blockers; mexiletine was added in three patients, and mexiletine and flecainide were added in one patient. Three (25%) patients experienced torsades de pointes while receiving beta-blockers, one of which was refractory to medical therapy. This patient underwent left cardiac sympathetic denervation and implantable cardioverter-defibrillator placement. Genotyping was available for 6 (50%) patients (2 SCN5A mutation, 4 KCNH2 mutation). At last follow-up, no mortality was observed. Follow-up QTc intervals had decreased (mean 480 ± 20 ms, range 450-507 ms, P <.002). Conclusion: Management of patients with LQTS and 2:1 AVB presents unique challenges. Despite historical data indicating poor prognosis, our study represents a cohort of high-risk LQTS patients with a relatively optimistic outcome. This finding reflects early diagnosis and intervention, coupled with improved management strategies, in the current era.

KW - Atrioventricular block

KW - Long QT syndrome

KW - Torsades de pointes

UR - http://www.scopus.com/inward/record.url?scp=77952539116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952539116&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2010.02.035

DO - 10.1016/j.hrthm.2010.02.035

M3 - Article

C2 - 20197117

AN - SCOPUS:77952539116

VL - 7

SP - 781

EP - 785

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 6

ER -